Edwards Lifesciences Corp (EW) Shares Sold by Watch Point Trust Co
Watch Point Trust Co lowered its position in Edwards Lifesciences Corp (NYSE:EW) by 23.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,032 shares of the medical research company’s stock after selling 613 shares during the period. Watch Point Trust Co’s holdings in Edwards Lifesciences were worth $389,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of EW. BlackRock Inc. lifted its position in shares of Edwards Lifesciences by 7.4% in the fourth quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after acquiring an additional 1,128,082 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Edwards Lifesciences by 21,360.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock worth $69,000 after buying an additional 10,587,326 shares during the period. FMR LLC lifted its holdings in Edwards Lifesciences by 28.9% during the fourth quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock worth $1,160,540,000 after buying an additional 1,700,199 shares during the period. Jennison Associates LLC lifted its holdings in Edwards Lifesciences by 184.7% during the fourth quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock worth $629,855,000 after buying an additional 2,667,749 shares during the period. Finally, Norges Bank purchased a new stake in Edwards Lifesciences during the fourth quarter worth $559,646,000. 84.88% of the stock is owned by institutional investors.
EW has been the subject of a number of analyst reports. Bank of America upped their target price on Edwards Lifesciences from $190.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Citigroup increased their price objective on Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a report on Wednesday, January 2nd. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a report on Wednesday, March 27th. They noted that the move was a valuation call. Deutsche Bank began coverage on Edwards Lifesciences in a report on Wednesday, January 2nd. They set a “hold” rating and a $164.00 price objective for the company. Finally, Morgan Stanley increased their price objective on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $182.29.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.17. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. The firm had revenue of $977.70 million for the quarter, compared to the consensus estimate of $973.72 million. During the same period in the prior year, the firm earned $0.94 EPS. Research analysts expect that Edwards Lifesciences Corp will post 5.22 earnings per share for the current year.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,474 shares of the stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $176.34, for a total transaction of $259,925.16. Following the sale, the vice president now directly owns 15,905 shares of the company’s stock, valued at approximately $2,804,687.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Larry L. Wood sold 6,716 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $192.34, for a total value of $1,291,755.44. Following the sale, the vice president now directly owns 122,495 shares in the company, valued at $23,560,688.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 114,328 shares of company stock worth $20,121,304. 1.63% of the stock is owned by insiders.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: How to Invest in a Bull Market
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.